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Abstract
Background: We used human papillomaviruses (HPV) as a model system to evaluate the utility of
a nucleic acid, hybridization-based bioelectronic DNA detection platform (eSensor™) in identifying
multiple pathogens.
Methods:  Two chips were spotted with capture probes consisting of DNA oligonucleotide
sequences specific for HPV types. Electrically conductive signal probes were synthesized to be
complementary to a distinct region of the amplified HPV target DNA. A portion of the HPV L1
region that was amplified by using consensus primers served as target DNA. The amplified target
was mixed with a cocktail of signal probes and added to a cartridge containing a DNA chip to allow
for hybridization with complementary capture probes.
Results: Two bioelectric chips were designed and successfully detected 86% of the HPV types
contained in clinical samples.
Conclusions: This model system demonstrates the potential of the eSensor platform for rapid and
integrated detection of multiple pathogens.
Background
Global emergence of pathogenic infectious diseases by
both natural and intentional means presents a formidable
challenge to infectious disease surveillance and response,
namely timely and efficient pathogen detection. Many
laboratory methods exist for identifying pathogens, but
most require exquisite care in sample handling and
processing prior to characterization of a pathogen. In
addition, costly and perishable reagents, equipment, and
supplies are required for sensitive and specific detection.
The ideal detection system would integrate sample
processing and pathogen characterization into a single
automated device that would eliminate laborious, and
time consuming sample processing and costly detection.
Bioelectronic detection of nucleic acids on a miniature
solid support is one of the first steps toward development
of such an integrated detection device.
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Bioelectronic DNA detection involves forming an elec-
tronic circuit mediated by nucleic acid hybridization and
it serves as the basis for a DNA detection system called
eSensor™ [1–4]. This system uses low-density DNA chips
containing electrodes coated with DNA capture probes.
Target DNA present in the sample hybridizes specifically
both to capture probes and ferrocene labeled signal
probes in solution thereby generating an electric current.
Current eSensor DNA chips contain as many as 36 elec-
trodes for simultaneous detection of multiple pathogens
from a single sample.
Many pathogens cause both acute and chronic disease at
relatively low copy number and may be difficult or impos-
sible to propagate in culture. Thus, most pathogen detec-
tion systems rely on nucleic acid amplification by using
polymerase chain reaction (PCR). One highly effective
amplification strategy targets conserved sequences among
the family of organisms of interest. Such broad-range PCR
strategies have been used to identify and characterize sev-
eral known and previously uncharacterized bacteria [5,6]
and viruses [7,8]. In order to maximize the utility of these
effective pathogen nucleic acid amplification systems,
amplification needs to be coupled with rapid, sensitive,
and specific detection. Bioelectronic DNA detection by
use of the eSensor chip might fulfill this need.
Human papillomaviruses (HPV) serve as an ideal model
system for determining the efficiency and feasibility of
eSensor DNA detection technology since there are at least
30 distinct genital HPV types that can be effectively ampli-
fied with broad-range consensus PCR primers [9]. We
designed two eSensor chips, each containing 14 probes
specific for the conserved L1 region of the HPV genome.
We evaluated clinical cervical cytology samples known to
contain one or more HPV types. The eSensor DNA detec-
tion platform successfully detected the correct HPV type in
most of these clinical samples, demonstrating that the sys-
tem provides a rapid, sensitive, specific, and economical
approach for multiple-pathogen detection and identifica-
tion from a single sample.
Methods
eSensor™ DNA Chip Design
We used previously described printed circuit board tech-
nology to manufacture eSensor chips with 16 gold elec-
trodes, one reference electrode, and one auxiliary
electrode [2–4]. Each electrode was wired to a connector
at the edge of the chip. Capture probes were synthesized
using an alkane chain of 16 residues terminated at the 3'-
end with a disulfide which was spotted onto the gold elec-
trode on the chips to form a self-assembled monolayer
[10]. The chips were glued into a plastic housing with a
port for sample introduction.
Hybsimulator (RNAture, Inc., Irvine, CA) was used to
design the HPV target mimics, and signal and capture
probes. For these experiments, we designed capture (Table
1) and signal (Table 2) probes to hybridize specifically to
the exon sequence of β-globin and to HPV sequences
within the 450-bp L1 region amplified by the PGMY
primer set. Signal probes (Table 2) tagged with eight fer-
rocenes were synthesized with a modified adenine residue
(N6) containing a ferrocene substitution on the ribose
ring [11]. No signal probes were synthesized for HPV
types 33, 39, 55, and 73. HPV target mimic oligonucle-
otides were synthesized for types 6, 11, 16, 18, 26, 31, 35,
40, 42, 45, 51, 52, 54, 56, 58, 59, 66, 68, 82, 83, and 84
(Table 3).
Sample selection and DNA extraction
Residual ThinPrep (Cytyc Corporation, Boxborough, MA)
cervical samples previously tested for HPV using the
Roche line blot assay [9] were used in this study. Twenty
samples containing 24 of the 27 HPV types on the reverse
line blot were selected for extraction and testing. (No sam-
ples were positive for HPV 53, 55, and 57.) Therefore a
total of 21 HPV types could be evaluated (there were 22
HPV capture and signal probes minus no clinical sample
containing HPV 53 leaves 21 possible HPV type answers).
Samples were coded so that investigators were blinded to
the presence of multiple HPV types. DNA was extracted
from 250 µL aliquots by using the QIAmp DNA Mini Kit
(QIAGEN Inc., Valencia, CA). The procedure provided
with the kit was followed except that the proteinase K
digestion was done overnight at 56°C. Following DNA
elution from the column, DNA was concentrated in a
Centricon Centrifugal Filter Device YM-100 (Millipore
Corporation, Bedford MA) according to manufacturer's
specifications. Each DNA sample was brought to 50 µL
with the addition of ultra pure water.
HPV PCR and Typing
Five microliters of purified DNA from cytology samples
was used in each PCR assay. HPV DNA was amplified with
the PGMY09/PGMY11 primer system that uses a multi-
plex format to amplify both HPV and β-globin in the same
tube [9]. To allow for strand separation, only the down-
stream primers designated PGMY11 and one β-globin
primer were biotinylated (Table 1). The use of one bioti-
nylated primer to amplify the product was still sufficient
to verify the amplified HPV type by reverse line blot.
Amplification without DNA template was used to moni-
tor contamination.
Avidin-coated beads were used to harvest the biotin-
labeled DNA strand from 50 µl of product. The biotin-free
DNA strand was then used in the assay. Briefly, the target
mimic or target DNA was mixed with a signal probe cock-
tail (125 nM of each signal probe) in a hybridizationBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/12
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buffer (proprietary). This mixture was injected into the
eSensor chip for hybridization at 40°C for 2 to 8 hours.
The chips were then scanned by an AC voltammetry tech-
nique built into the eSensor detection device called the
eSensor 4800, from -50 to +550 millivolts, to detect and
interpret the electrochemical signal generated during
hybridization. Investigators recording eSensor results
remained blinded to prior or current HPV results.
Forty microliters of the amplified products was also inde-
pendently tested for HPV using a reverse line probe assay
(typing strip and reagents generously provided by Janet
Kornegay, Roche Molecular Systems, Inc., Alameda, CA).
In each case the HPV results on the strip were concordant
with prior results. HPV detection and typing results from
eSensor and Roche were then directly compared.
Results
The electrochemical signal is generated when the HPV
amplicon hybridizes to the capture probe and ferrocene-
labeled signal probe, thereby bringing the reporter mole-
cule, ferrocene, into contact with the self-assembled
monolayer on the gold electrode (Fig. 1). An alternating
current voltammogram is obtained when HPV is detected
in a sample but no electronic signal is registered when
HPV DNA is absent from the sample. (Fig. 2).
Table 1: Human papillomavirus (HPV) capture probe and PCR primers sequences.
6 capture CAG AAT TGG TGT ATG TGG AAG A(N152)
11 capture TAA TCT GAA TTA GTG TAT GTA GCA GAT TTA GAC A(N152)
16 capture GTA GTT TCT GAA GTA GAT ATG G(N152)
18 capture TGG TAG CAT CAT ATT GCC CAG G(N152)
26 capture ATC AGA TGG TTT AAA TGG AGT GGA TGC(N152)
31 capture TAC TAC TTT TAA ATG TAG TAT CAC(N152)
35 capture ACT GTC ACT AGA AGA CAC AGC AGA ACA CA(N152)
40 capture GGG GGA CTG TGT GGC ACC A(N152)
42 capture AGC AGC TGT ATA TGT ATC ACC AGA TGT TGC AGT GGC TCA(N152)
45 capture CTT AGT AGG GTC ATA TGT ACT TGG C(N152)
51 capture TTG GGG AAA CCG CAG CAG TGG CAG GGC TA(N152)
52 capture TAT GTG CTT TCC TTT TTA ACC T(N152)
54 capture GTC AGA ATT ATT AAA GCT ATC CTG CG(N152)
56 capture TTT TCG TGC ATC ATA TTT ACT TA(N152)
58 capture GTA CCT TCC TTA GTT ACT TCA G(N152)
59 capture CTG GTA GGT GTG TAT ACA TTA G(N152)
66 capture CAC GGG CAT CAT ATT TAG TTA A(N152)
68 capture TTA AAT TTA TTA GGA TCA TAA ATA TTT GGT A(N152)
82 capture AAT GTT TGT GCA ACA GAT TGA GTA ACA GCT GTG(N152)
83 capture GTT AGA GGC TGT GTA TTC ATT AGC(N152)
84 capture GGT TTA TAT TCT GAT TCG GTG T(N152)
globin capture AGC AAT AGA TGG CTC TGC CC(N152)
globin primer GAA GAG CCA AGG ACA GGT AC
globin rev primer BIOTIN CAA CTT CAT CCA CGT TCA CC
HMB01 rev primer BIOTIN GCG ACC CAA TGC AAA TTG GT
PGMY09F primer BIOTIN CGT CCC AAA GGA AAC TGA TC
PGMY09G primer BIOTIN CGA CCT AAA GGA AAC TGA TC
PGMY09H primer BIOTIN CGT CCA AAA GGA AAC TGA TC
PGMY09I primer BIOTIN GCC AAG GGG AAA CTG ATC
PGMY09J primer BIOTIN CGT CCC AAA GGA TAC TGA TC
PGMY09K primer BIOTIN CGT CCA AGG GGA TAC TGA TC
PGMY09L primer BIOTIN CGA CCT AAA GGG AAT TGA TC
PGMY09M primer BIOTIN CGA CCT AGT GGA AAT TGA TC
PGMY09N primer BIOTIN CGA CCA AGG GGA TAT TGA TC
PGMY09P primer BIOTIN GCC CAA CGG AAA CTG ATC
PGMY09Q primer BIOTIN CGA CCC AAG GGA AAC TGG TC
PGMY09R primer BIOTIN CGT CCT AAA GGA AAC TGG TC
PGMY11A primer GCA CAG GGA CAT AAC AAT GG
PGMY11B primer GCG CAG GGC CAC AAT AAT GG
PGMY11C primer GCA CAG GGA CAT AAT AAT GG
PGMY11D primer GCC CAG GGC CAC AAC AAT GG
PGMY11F primer GCT CAG GGT TTA AAC AAT GGBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/12
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Many of the HPV target mimics tested resulted in a specific
signal, with the exception of HPV types 16, 26, 35, 40, 42,
51, 52, and 82. This nonspecific hybridization signal gen-
erally resulted from a long stretch of complementary
sequences (6–8 bases) among the HPV types due to their
close genetic relatedness. Nonspecific hybridization was
eliminated by introducing a mismatched base to the com-
plementary region in the signal probes for HPV types 16,
26, 35, 42, and 82 and the capture probes for HPV types
40, 42, 51, 52, and 82. For instance, the HPV 16 signal
probe hybridized with both the HPV 16 target mimic (Fig.
3, left panel) and the HPV 52 capture probe (Fig. 3, center
panel). This cross-reactivity was eliminated by changing
the second A base in the 5'-end of signal probe to a G base
(Fig. 3, right panel). In addition, we demonstrated that
one base modification of the signal probe (Fig. 3, left and
right panels) generated minimal negative impact to the
assay signal level. Applying this strategy, we were able to
Table 2: HPV type and signal probe sequence.
6 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) TGT AGT TAC GGA TGC AC
11 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) CAG ATG CAG ATA GTG TCA T
16 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) CAG CGC ATA ATG ACA TAT TT
18 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) TAC AGG AGA CTG TGT AG
26 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) AGA TGC TGT AGA TAA TGT AC
31 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) TGT TTG CAA TTG CAG CA
35 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) CAG ACA TAT TTG TTC TAC GG
40 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) TAA GGT TAA ATT AGT GCA ACG A
42 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) CAA AGA CAT GTT AGT ACT AC
45 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) ACA GGA TTT TGT GTA GAG G
51 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) ATA GTT AAA TTT GTA CTT CTG G
52 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) CAG CAC ATA AAG TCA TG
54 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) TGG ATG CTG TAG CAC AC
56 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) ACT GTT CTG TAG CAG TAC T
58 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) TGC ATA ATG TCA TAT TAG TG
59 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) GAA TAG AAG AAG TAG TAG AA
66 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) TGT GCT TTT AGC TGC AT
68 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) CAG CTG ATT CAG TAG TAG TA
82 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) CTA ATG GTT AAA TTG GTA GTT
83 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) CTG TGT AGC AGG AGC TGA AA
84 (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) TGG TAG CAG CAC TAA TA
Globin (N6) C(N6) G(N6) C(N6) GCT TA(N6) C(N6) G(N6) C(N6) TGA CTT TTA TGC CCA GAC CTG G
Table 3: HPV type and target mimic oligonucleotide sequences
6 ACC ACA CGC AGT ACC AAC ATG ACA TTA TGT GCA TCC GTA ACT ACA TCT TCC ACA TAC ACC AAT TCT GAT TAT AAA
11 GTA CAA ATA TGA CAC TAT GTG CAT CTG TGT CTA AAT CTG CTA CAT ACA CTA ATT CAG ATT ATA AGG AAT ACA TGC G
16 ACT ACA CGC AGT ACA AAT ATG TCA TTA TGT GCT GCC ATA TCT ACT TCA GAA ACT ACA TAT AAA AAT ACT AAC TTT AA
18 ACC ACT CCC AGT ACC AAT TTA ACA ATA TGT GCT TCT ACA CAG TCT CCT GTA CCT GGG CAA TAT GAT GCT ACC AAA T
26 GTA CTA ACC TTA CCA TTA GTA CAT TAT CTG CAG CAT CTG CAT CCA CTC CAT TTA AAC CAT CTG ATT ATA AAC AAT T
31 ACC ACA CGT AGT ACC AAT ATG TCT GTT TGT GCT GCA ATT GCA AAC AGT GAT ACT ACA TTT AAA AGT AGT AAT TTT AA
35 TGT AGT TGA TAC AAC CCG TAG TAC AAA TAT GTC TGT GTG TTC TGC TGT GTC TTC TAG TGA CAG TAC ATA TAA AAA T
40 AGT TGT AGA CAC CAC TCG TAG CAC TAA TTT AAC CTT ATG TGC TGC CAC ACA GTC CCC CAC ACC AAC CCC ATA TAA T
42 ACT ACC CGT AGT ACT AAC ATG ACT TTG TGT GCC ACT GCA ACA TCT GGT GAT ACA TAT ACA GCT GCT AAT TTT AAG G
45 AAC ATT ATG TGC CTC TAC ACA AAA TCC TGT GCC AAG TAC ATA TGA CCC TAC TAA GTT TAA GCA GTA TAG TAG ACA T
51 GTT GAT ACT ACC AGA AGT ACA AAT TTA ACT ATT AGC ACT GCC ACT GCT GCG GTT TCC CCA ACA TTT ACT CCA AGT A
52 ACC ACT CGT AGC ACT AAC ATG ACT TTA TGT GCT GAG GTT AAA AAG GAA AGC ACA TAT AAA AAT GAA AAT TTT AAG
54 GTA CTA ACC TAA CAT TGT GTG CTA CAG CAT CCA CGC AGG ATA GCT TTA ATA ATT CTG ACT TTA GGG AGT ATA TTA G
56 GTA CTA ACA TGA CTA TTA GTA CTG CTA CAG AAC AGT TAA GTA AAT ATG ATG CAC GAA AAA TTA ATC AGT ACC TTA G
58 ACC ACT CGT AGC ACT AAT ATG ACA TTA TGC ACT GAA GTA ACT AAG GAA GGT ACA TAT AAA AAT GAT AAT TTT AAG
59 ACT ACT CGC AGC ACC AAT CTT TCT GTG TGT GCT TCT ACT ACT TCT TCT ATT CCT AAT GTA TAC ACA CCT ACC AGT
66 ACT ACC AGA AGC ACC AAC ATG ACT ATT AAT GCA GCT AAA AGC ACA TTA ACT AAA TAT GAT GCC CGT GAA ATC AAT
68 GTA CCA ATT TTA CTT TGT CTA CTA CTA CTG AAT CAG CTG TAC CAA ATA TTT ATG ATC CTA ATA AAT TTA AGG AAT A
82 ACT ACT AGA AGT ACC AAT TTA ACC ATT AGC ACT GCT GTT ACT CAA TCT GTT GCA CAA ACA TTT ACT CCA GCA AAC T
83 GTA CCA ATA TTA CTA TTT CAG CTG CTG CTA CAC AGG CTA ATG AAT ACA CAG CCT CTA ACT TTA AGG AAT ACC TCC G
84 ACC ACC CGC AGC ACC AAT TTT ACT ATT AGT GCT GCT ACC AAC ACC GAA TCA GAA TAT AAA CCT ACC AAT TTT AAG
globin GGG AGG GCA GGA GCC AGG GCT GGG CAT AAA AGT CAG GGC AGA GCC ATC TAT TGC TTA CAT TTG CTT CTG ACA CAA CBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/12
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effectively reduce the cross-reactivity among the signal
and capture probes for those HPV types where problems
of non-specific signal had initially been encountered
without compromising hybridization strengths.
In most instances for the 20 samples tested, there was per-
fect concordance between the HPV type(s) detected by
reverse line blot and the eSensor system (Table 4). The
eSensor detected 18 (86%) of 21 HPV types. In samples
with multiple HPV types amplified by the consensus
primer system and typed by reverse line blot (but blinded
to the individual conducting the eSensor assay), the
eSensor successfully detected the multiple HPV targets in
all six samples (Table 4).
Discussion
We have presented a model application of a novel elec-
tronic detection platform [1–4]. We used HPV as a model
infectious disease system because consensus primers are
available that amplify at least 30 closely related genital
HPV types. The resulting amplicons are extremely similar,
and this relatedness challenges the ability of the eSensor
technology to distinguish accurately among these patho-
gens. The first optimization steps involved evaluation of
electrochemical signal generation by using HPV target
mimics. Cross-hybridization was observed between a sub-
set of HPV target mimics and the capture and signal
probes. This cross-hybridization was easily overcome by
the introduction of mismatched base pairs. The effective-
Figure 1
Schematic represention of the eSensor DNA Detection System. A self-assembled monolayer is generated on a gold electrode. 
For electrochemical detection to occur across the monolayer, two hybridization events must occur: the first between the cap-
ture probe (shown in black perpendicular to the electrode) and the target (for example, HPV DNA, shown in gray), and the 
second between an adjacent region of the target and ferrocene labeled signal probe (shown in black parallel to the monolayer).
3’
5’
Self-Assembled Monolayer
5’
Gold electrode
Fe
Fe
Fe
Ferrocene LabelsBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/12
Page 6 of 9
(page number not for citation purposes)
ness of single-base mismatch discrimination of the eSen-
sor has been demonstrated by using wild type and mutant
strains of human immunodeficiency virus [3].
We used the eSensor DNA chip to determine the presence
of single or multiple HPV types in cervical cytology sam-
ples. While the presence of the target HPV type was
known, the presence of other HPV types in the same
sample remained blinded (e.g., the HPV 42 in a clinical
sample was identified but the presence of HPV 68 in the
same sample was not known to those performing electro-
chemical detection). There was good concordance for the
detection of the target HPV type by the eSensor DNA
Detection System. Eighteen (86%) of 21 target HPV types
represented on the chip were readily detected by the eSen-
sor (Table 4); HPV 40, 45 and 54 were not detected. Some
of the other discrepancies could be due to lack of rigorous
optimization of sensitivity parameters for the eSensor sys-
tem, such as the weak HPV 54 result on reverse line blot
and lack of detection on eSensor. Low-level signals on the
line probe assay have been validated by sequencing the
amplified product [12]. For HPV 40 discrepancy, the
capture probe design may not have been optimal to allow
for hybridization with the HPV 40 target. These HPV types
may be variant types that did not hybridize to the capture
probe and subsequently could not be detected by the sig-
nal probe. Not only are there over 200 HPV types, but sev-
eral sequence variants of HPV types are known to exist
[13]. Most hybridization reactions could be analyzed after
2 hours, although in several instances up to 8 hours of
Figure 2
The eSensor™ bioelectronic representative signal output. A fourth harmonic alternating current voltammogram is obtained 
from an HPV-positive sample (left panel), and one obtained from an HPV-negative sample (right panel). The faradic signal in the 
fourth harmonic closely fits the third derivative of a Gaussian curve. The peak current (100 nA) in the fourth harmonic voltam-
mogram is determined by averaging the two peaks that center around 130 mV.
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hybridization time was required. The intent of this study
was to use HPV as a model system to assess the feasibility
of electrochemical detection with the eSensor chip of mul-
tiple pathogens, not to achieve perfect concordance of
HPV detection with the reverse line blot.
In this model assay, we have performed optimization of
probe sequences and assay protocol by using synthesized
target mimics. The resultant assay correctly identified
nearly all HPV type in the clinical samples. No attempt to
further optimize the assay using PCR amplicons, rather
than target mimics, was made and neither was the PCR
process optimized for detection by using the eSensor DNA
detection system. This work demonstrates the ease with
which a multi-analyte panel assay can be prototyped
using the eSensor DNA detection system. For clinical
applications, the prototype assay can be readily fine-tuned
by optimizing the conditions for PCR and hybridization
to yield concordance levels approaching 100% (data not
published).
Conclusions
The bioelectronic detection platform described here
includes disposable DNA chips and laboratory-based elec-
tronic readers and is a first-generation system that ulti-
mately will facilitate the development of relatively low
Figure 3
HPV 16 Signaling Probe Optimization. The HPV eSensor™ chip was decorated with 11 different HPV capture probes and an 
HIV capture probe as a negative control (shown in x-axis). An HPV 16 target mimic was detected by the eSensor in the pres-
ence of HPV 16 specific signaling probe (left panel) in which the sample also reacted with HPV 52-specific capture probe. The 
signal was identified as being from the hybridization between HPV 16 signal probe and the HPV 52 capture probe as shown in 
the mid-panel in which HPV 16 signal probe was introduced into the chip without any target mimic. The HPV 16 signal probe 
was modified replacing the second A base in the 5'-end with a G base. The resulted new signal probe hybridized specifically 
with the HPV 16 target mimic and did not cross-react with the HPV 52 capture probe.
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cost, arrayed nucleic acid-based tests. For widespread
clinical laboratory adoption, these arrays must have clini-
cally appropriate densities compatible with the needs of
molecular diagnostics laboratories, (i.e., low cost and not
labor-intensive). The system described could also be
developed as a foundation for devices to be used for
point-of-care testing for other infectious diseases.
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